Drug-resistant TB: latest news

Drug-resistant TB features

Drug-resistant TB news from aidsmap

  • MDR-TB numbers could keep growing despite improved treatment

    Up to one-in-three tuberculosis cases in Russia could be multidrug resistant by 2040, and one-in-eight in India, unless more is done to stop the person-to-person spread of drug-resistant TB and sub-optimal treatment, a modelling study published ...

    11 May 2017 | Keith Alcorn
  • Three-drug regimen beats XDR-TB in first trial

    A regimen of three oral drugs given for six months was enough to clear extensively drug-resistant tuberculosis (XDR-TB) in 29 of the first 31 people to have completed the treatment course, Dr Francesca Conradie of Sizwe Tropical Disease Hospital, ...

    17 February 2017 | Keith Alcorn
  • Shortened regimen for MDR-TB shows good results for children

    The use of the shortened 9-month treatment regimen for multidrug-resistant tuberculosis (MDR-TB), known as the ‘Bangladesh regimen’ has shown to be successful in 83% of children and adolescents diagnosed with rifampicin-resistant (RR) TB. The findings were presented at TB2016, a ...

    18 July 2016 | Lesley Odendal
  • South Africa’s XDR-TB epidemic is due to transmission rather than evolution of resistant strains

    A study in KwaZulu-Natal, South Africa, evaluating the social networks as well as clinical and genotypic data from individuals with extensively drug resistant tuberculosis (XDR-TB) has concluded that transmission – in both hospitals and households – has been the primary ...

    04 March 2016 | Theo Smart
  • Empirical TB treatment comes up short again

    A South African trial has found that a strategy allowing primary care nurses to quickly provide empirical tuberculosis (TB) treatment for newly diagnosed people with advanced HIV disease at very high risk of, but without confirmed, TB did not ...

    26 February 2016 | Theo Smart
  • MDR-TB treatment: Six drugs better than five

    A regimen containing six drugs was more likely to cure multi-drug resistant tuberculosis (MDR-TB) than a regimen containing five drugs, a nine-country observational study has shown. The study also found that each active drug in the ...

    13 January 2016 | Keith Alcorn
  • Xpert MTB/RIF testing has reduced MDR-TB treatment delays in South Africa

    Although the introduction of the Xpert MTB/RIF test for TB and drug-resistant TB has improved the time from clinic presentation to second-line treatment in South Africa since 2011, improved access to treatment and a reduction in delays of treatment ...

    07 January 2016 | Lesley Odendal
  • One in eight children with confirmed TB have drug-resistant TB in Cape Town

    One in eight children with confirmed TB have drug-resistant TB in Cape Town, South Africa, according to a surveillance study of childhood TB drug-resistance, presented by Professor Simon Schaaf at the 46th Union World Conference on Lung Health held ...

    05 January 2016 | Lesley Odendal
  • Death during MDR-TB treatment more likely in people with HIV and underweight or most drug-resistant patients

    People living with HIV, those who are underweight and those with more extensive drug resistance are more likely to die during treatment for multi-drug resistant tuberculosis (MDR-TB), a nine-country study has found. The findings were presented at the 46th ...

    10 December 2015 | Keith Alcorn
  • 9-month MDR-TB regimen cures 82% in African study

    A 9-month standardised treatment regimen for multi-drug resistant tuberculosis (MDR-TB) cured 82% of people recruited to an observational study in Francophone Africa, the 46th Union World Conference on Lung Health heard on Saturday in Cape Town. The regimen showed similar ...

    07 December 2015 | Keith Alcorn
More news

Drug-resistant TB news selected from other sources

  • People still being denied improved treatment for multidrug-resistant TB

    People with multidrug-resistant tuberculosis (MDR-TB) are still not receiving two newer TB drugs, bedaquiline and delamanid, which have been available for more than four years and have shown improved cure rates for the disease, deplored Médecins Sans Frontières (MSF) at the 48th Union World Conference on Lung Health in Guadalajara, Mexico, where the global TB community is meeting.

    16 October 2017 | Médecins Sans Frontières (MSF) International
  • STREAM clinical trial results provide vital insight into nine-month treatment regimen for multidrug-resistant tuberculosis

    Preliminary results - released today at the 48th Union Conference on Lung Health - from Stage 1 of the STREAM randomised clinical trial show that the nine-month treatment regimen being tested achieved favourable outcomes in almost 80 percent of those treated. The results suggest the nine-month regimen is very close to the effectiveness of the 20-24 month regimen recommended in the 2011 WHO guidelines, when both regimens are given under trial conditions.

    16 October 2017 | 48th Union World Conference on Lung Health
  • In Early Results, Shorter Treatment for Tuberculosis Proves Effective

    Taking the right antibiotics for just nine months may be as effective against drug-resistant tuberculosis as taking them for two years, as is currently recommended, according to preliminary findings from an international study.

    16 October 2017 | New York Times
  • TB Alliance Moves Two Novel Tuberculosis Drugs into Human Trials

    TBA-7371 and Sutezolid Help Fill Sparse Pipeline of New Antibiotics Against a Disease That Grows Increasingly Resistant to Older Drugs.

    11 October 2017 | TB Alliance
  • Ukraine’s TB problem is ticking time bomb for Europe

    Controlling the airborne disease takes on additional urgency this year as the country seeks to integrate into EU with a new visa-free regime.

    29 August 2017 | Politico
  • X-DR TB emerged in 1990s in South Africa fueled by HIV

    Extensively drug resistant tuberculosis emerged and was widely transmitted in South Africa long before it was spotted by public health surveillance efforts, and at least a decade earlier than the first reported outbreak in 2005, a  presentation Monday showed.

    26 July 2017 | Science Speaks
  • We had to run our own trial for TB drugs – nobody else was doing it

    Four years ago, Médecins Sans Frontières (MSF) made the decision to sponsor and run its own tuberculosis clinical trial. The aim was to find a new treatment regimen for drug-resistant tuberculosis (TB) that was radically better than what was currently available. As an organisation that specialises in delivering short-term emergency healthcare, this was a bold and new direction to take. But it was a decision that came from our frustration, anger and impatience on behalf of the more than 20,000 people with TB that we treat every year. We felt compelled to search for improved treatments ourselves because too few pharmaceutical companies, organisations or universities were doing enough about it.

    02 June 2017 | The Guardian
  • Multidrug-resistant tuberculosis in migrants, multi-country cluster

    A multi-country cluster of multidrug-resistant tuberculosis (MDR TB) involving 28 migrants has been delineated by whole genome sequencing (WGS) in migrants recently having arrived from countries in the Horn of Africa. Although the number of cases detected so far is small, there is a possibility that more cases associated with this cluster may still be identified.

    14 April 2017 | ECDC
  • Tuberculosis: Fewer than five per cent of people in need are treated with new drugs

    Outside of a small number of clinical trials and compassionate use programmes, only 469 people received delamanid in 2016, while just over 4,300 received bedaquiline. All other people receiving DR-TB treatment continue instead to be treated with older, more toxic regimens that cure only 50 per cent of people treated, and cause severe side-effects, ranging from deafness to psychosis.

    27 March 2017 | Médecins Sans Frontières (MSF) International
  • TB Alliance Sublicenses Promising Anti-tuberculosis Drug from the Medicines Patent Pool

    On World Tuberculosis Day, TB Alliance and the Medicines Patent Pool (MPP) announced a licensing agreement for the clinical development of sutezolid, an antibiotic drug candidate which demonstrated encouraging results in early studies. The sublicense pertains to the development of sutezolid in combination with other TB drugs and follows the MPP's license for the treatment signed with patent holder The Johns Hopkins University in January.

    24 March 2017 | Yahoo Finance
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.

See also

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.